These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31498425)

  • 1. Clinical and immunological characterization of 14 cases of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: a single-centre study.
    Hayashi M; Tsunoda T; Sato F; Yaguchi Y; Igarashi M; Izumi K; Nishie W; Ishii N; Okamura K; Suzuki T; Hashimoto T
    Br J Dermatol; 2020 Mar; 182(3):806-807. PubMed ID: 31498425
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of dipeptidyl peptidase-4 inhibitor-related anti-BP230-type bullous pemphigoid showing granular C3 dermatosis-like direct immunofluorescence staining.
    Hashimoto T; Tsunoda T; Arai Y; Izumi K; Ishii N; Qian H; Li X; Tsuruta D
    Eur J Dermatol; 2022 Jul; 32(4):549-551. PubMed ID: 36301770
    [No Abstract]   [Full Text] [Related]  

  • 3. Dipeptidyl Peptidase-4 Inhibitor Induced Bullous Pemphigoid Complicated by Acquired Reactive Perforating Dermatosis.
    Gambichler T; Espey B; Doerler M; Stranzenbach R
    Actas Dermosifiliogr; 2022 Oct; 113(9):914-915. PubMed ID: 35636509
    [No Abstract]   [Full Text] [Related]  

  • 4. Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor.
    Kano Y; Kato M
    CMAJ; 2022 May; 194(20):E705. PubMed ID: 35609911
    [No Abstract]   [Full Text] [Related]  

  • 5. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab.
    Garrido PM; Alexandre MI; Travassos AR; Filipe P
    Dermatol Ther; 2020 Nov; 33(6):e14160. PubMed ID: 32770711
    [No Abstract]   [Full Text] [Related]  

  • 6. Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    García-Díez I; España A; Iranzo P
    Br J Dermatol; 2019 May; 180(5):1267-1268. PubMed ID: 30675718
    [No Abstract]   [Full Text] [Related]  

  • 7. Neutrophil to lymphocyte ratio is predictive of severe complications and mortality in patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective longitudinal observational study.
    Sugiyama S; Yamamoto T; Aoyama Y
    J Am Acad Dermatol; 2022 Jun; 86(6):1387-1390. PubMed ID: 34058280
    [No Abstract]   [Full Text] [Related]  

  • 8. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
    Front Immunol; 2022; 13():843480. PubMed ID: 35309321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors and impact of their withdrawal].
    Martín-Enguix D; Ruiz-Villaverde R; Galán-Gutiérrez M; Cabrerizo-Carvajal AM
    Aten Primaria; 2023 Apr; 55(4):102586. PubMed ID: 36842360
    [No Abstract]   [Full Text] [Related]  

  • 10. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid.
    Gravani A; Christou P; Tigas S; Bassukas ID
    An Bras Dermatol; 2021; 96(6):782-784. PubMed ID: 34600789
    [No Abstract]   [Full Text] [Related]  

  • 12. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading.
    Takama H; Yoshida M; Izumi K; Yanagishita T; Muto J; Ohshima Y; Nishie W; Shimizu H; Akiyama M; Watanabe D
    Acta Derm Venereol; 2018 Nov; 98(10):983-984. PubMed ID: 30085319
    [No Abstract]   [Full Text] [Related]  

  • 13. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis.
    Hung CT; Chang YL; Wang WM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus.
    Chanprapaph K; Pratumchart N; Limtong P; Rutnin S; Sukasem C; Kungvalpivat P; Triamchaisri S; Suchonwanit P
    J Dermatol; 2021 Apr; 48(4):486-496. PubMed ID: 33543537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
    Mai Y; Nishie W; Izumi K; Yoshimoto N; Morita Y; Watanabe M; Toyonaga E; Ujiie H; Iwata H; Fujita Y; Nomura T; Sato-Matsumura KC; Shimizu S; Shimizu H
    Br J Dermatol; 2018 Sep; 179(3):790-791. PubMed ID: 29624639
    [No Abstract]   [Full Text] [Related]  

  • 17. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
    Lindgren O; Varpuluoma O; Tuusa J; Ilonen J; Huilaja L; Kokkonen N; Tasanen K
    Acta Derm Venereol; 2019 May; 99(6):602-609. PubMed ID: 30848289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
    Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
    Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
    Patsatsi A; Kyriakou A; Meltzanidou P; Trigoni A; Lamprou F; Kokolios M; Giannakou A
    Eur J Dermatol; 2018 Oct; 28(5):711-713. PubMed ID: 30325322
    [No Abstract]   [Full Text] [Related]  

  • 20. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
    Lambadiari V; Kountouri A; Kousathana F; Korakas E; Kokkalis G; Theotokoglou S; Palaiodimou L; Katsimbri P; Ikonomidis I; Theodoropoulos K; Papadavid E
    BMC Endocr Disord; 2021 Feb; 21(1):23. PubMed ID: 33573656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.